A side-by-side look at two leading incretin-class molecules: mechanism, half-life, and what head-to-head trials show.
Semaglutide and tirzepatide are two of the most discussed peptides in metabolic research. They share a family but differ meaningfully in mechanism.
Semaglutide is a single-receptor agonist targeting GLP-1. Tirzepatide is a dual agonist, hitting both GIP and GLP-1 receptors. That dual action is the headline difference and likely explains the larger average effects reported in head-to-head clinical work.
Both molecules are engineered for weekly dosing. Semaglutide has a half-life around 7 days; tirzepatide around 5. In practice, both support once-weekly administration in published trials.
The SURMOUNT and SURPASS programs include direct comparisons. Tirzepatide tends to produce greater average reductions in body weight and HbA1c, though individual response varies and tolerability profiles differ.
Editorial overview only. All peptide products referenced are intended solely for research, investigational, or licensed professional use. Conduct your own research and consult a trusted, licensed medical practitioner before any personal or clinical use.
| Peptide | Category | Summary |
|---|---|---|
| Semaglutide | Metabolic & Weight | Semaglutide is a long-acting GLP-1 receptor agonist with one of the deepest clinical-trial datasets in metabolic medicine. It supports glucose-dependent insulin secretion, slows gastric emptying, and acts on central appetite pathways. |
| Tirzepatide | Metabolic & Weight | Tirzepatide is the first FDA-approved dual GIP/GLP-1 receptor agonist. By engaging two incretin pathways at once, head-to-head trials suggest larger average effects on weight and HbA1c than single-pathway GLP-1 agonists. |
Published 2026-06-13 by the Clarity Wellness editorial team. Approximate reading time: 7 minutes. Our sourcing and review policy is published at /editorial-standards.
All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.